Siemens Healthineers Navigates Spin-Off Delays and Operational Headwinds

Siemens Healthineers shares fall ~15% YTD due to delayed spin-off and operational headwinds in China. Q1 results show mixed performance, but full-year guidance holds.

Siemens Healthineers shares are trading near 38 euros, a decline of roughly 14 to 15 percent since the start of the year, as the company contends with a delayed corporate overhaul and persistent challenges in its core business. Investors are awaiting clarity on both fronts, with the next quarterly report due on May 7 seen as a critical indicator.

The planned spin-off, a major strategic move, has hit a snag. Siemens AG intends to distribute 30 percent of its Healthineers stake directly to its own shareholders, reducing its holding from about 67 percent to below 20 percent. Management had previously committed to providing concrete details by early in the second calendar quarter but has now confirmed the process will take longer than initially hoped. While this delay is a disappointment, some analysts note that many investors were already skeptical of a faster timeline.

Operational performance adds to the pressure. First-quarter results for 2026 showed a mixed picture: revenue grew by 3.8 percent, but adjusted earnings per share fell 3 percent to 0.49 euros. The diagnostics division was a primary drag, with revenue shrinking by 3 percent. Company leadership attributes this weakness largely to China, where a state anti-corruption campaign and centralized procurement processes have significantly dampened local sales.

External macroeconomic factors are also weighing on the outlook. The company anticipates new US tariffs will negatively impact adjusted EBIT by approximately 400 million euros this year. Additional headwinds from unfavorable currency effects are expected to pressure operating results by a further 200 to 250 million euros. Despite these challenges, the full-year guidance remains unchanged, targeting comparable revenue growth of 5 to 6 percent and adjusted earnings per share between 2.20 and 2.40 euros.

Amid these difficulties, the company is pushing forward with its technological agenda. At the DMEA healthcare trade fair in Berlin, running until April 23, it is showcasing new developments in precision medicine. The event also serves as a platform for Martin Stumpe, the incoming Chief Technology Officer set to officially begin his role on June 1. Stumpe, with a background that includes work at Google Brain and leading AI at Danaher, is tasked with accelerating the company's technological transformation, with a focus on "Patient Twinning" for advanced diagnostics.

There is a bright spot in the pipeline. Healthineers recently signed a clinical supply agreement with Radiopharm Theranostics to manufacture and distribute the imaging agent RAD101 for a Phase 3 trial in the United States. The agent, which has FDA Fast-Track status, is designed to differentiate true tumor recurrence from treatment-related changes in brain metastases—a known weakness of conventional MRI. It addresses an annual market of over 300,000 cases in the US alone.

Market observers are maintaining a measured stance. RBC Capital Markets recently reaffirmed its "Outperform" rating on the stock with a 55-euro price target. The bank suggests that while the spin-off delay is a short-term negative, potential revenue and margin improvement in the second half of the year could provide support. All eyes are now on the upcoming quarterly figures to see if the diagnostics division shows signs of stabilization and whether management can finally provide a clearer timeline for its corporate separation.